The Conversation (0)
Sunshine Biopharma Inc. (OTCQB:SBFM) announced the completion of several new IND-Enabling studies, including one in which the cytotoxic activity of Adva-27a.
Sunshine Biopharma Inc. (OTCQB:SBFM) announced the completion of several new IND-Enabling studies, including one in which the cytotoxic activity of Adva-27a.
Sunshine’s primary oncology drug candidate, was measured in the HMEC cell line, which indicated:
The data of the present HMEC studies indicated that concentrations of up to 24 micromolar of Adva-27a did not appreciably inhibit the normal growth process of these cells.
Dr. Steve N. Slilaty, CEO of Sunshine Biopharma stated:
These data indicate that Adva-27a will likely not be toxic or damaging to healthy tissue, a key component for our planned clinical trials, as toxicity is what stops most drugs in early development. This further confirms that Adva-27a will have great utility for cancer therapy in humans, particularly in view of the fact that twenty-four micromolar is over three times the actual concentration estimated to ultimately be used in patient therapy.
Click here to view the full press release.
